"CEO Sam Hupert Mayo is arguably one of the most recognised medical institutions in the US, if not the world, so winning this deal will most likely have a positive impact on our sales pipeline, exactly how much is hard to predict. However, we expect that most large institutions will at least consider us when putting out an RFP, which hopefully will translate to us getting to the starting line more often. Then to some degree it’s up to us, but having another key reference site will mean a lot, particularly to the academic/teaching hospitals and large health systems. It will confirm to them that Visage can handle big and complex environments such as theirs, which I believe will have a further positive impact on the pipeline"
PME Price at posting:
$5.14 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)